HUMAN HERPES VIRUS-6 (HHV-6) INCREASES EXPRESSION OF HUMAN PAPILLOMA VIRUS (HPV) GENES IN MALIGNANT AND NONMALIGNANT CERVICAL CELLS (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

HUMAN HERPES VIRUS-6 (HHV-6) INCREASES EXPRESSION OF HUMAN PAPILLOMA VIRUS (HPV) GENES IN MALIGNANT AND NONMALIGNANT CERVICAL CELLS (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A2341 1992. Unique Identifier : AIDSLINE ICDB/92684897
DiPaolo JA; Chen MC; Corbellino M; Ablashi DV; NCI, Bethesda, MD 20892

Abstract: Evidence associates HPVs as 1 factor in cervical cancer. This study examined the relationship between expression of HPV-16 or HPV-18 genes and HHV-6. HHV-6 transactivates HIV-1 LTR (HIV-1 has been found in cervicitis) suggesting that HHV-6 infection may affect other viruses such as cervical HPVs. Cervical HPV immortalized (HCX16-2 and 16-5) and tumor lines (C4-1 and QGH) were infected with 1000 TCID50 of HHV-6 (GS strain) for 2 hr at 37 C. After 3, 7 and 14 day, immunofluorescence with 2 HHV-6 monoclonal antibodies and PCR proved the presence of HHV-6. No cytopathic effect was observed as occurs with T cells (HSB2). All infected cell lines showed 15-20% HHV-6 antigen. HHV-6 DNA was detected by PCR by 3 days. HPV-16 and -18 expression as detected by Northern blot was amplified 2-fold. Because of the low frequency of cells showing the HHV-6 antigen, it is concluded that HPV amplification was in the order of 10-fold. This is the first evidence that human cervical epithelium can be infected with HHV-6. Furthermore, HHV-6 can amplify HPV genes and, therefore, is a potential cofactor for cervical cancer development.

Keywords: Antibodies, Monoclonal Antigens, Viral/ANALYSIS/GENETICS Blotting, Northern Cell Line Cell Line, Transformed Cervix Neoplasms/*MICROBIOLOGY Cervix Uteri/*MICROBIOLOGY DNA, Viral/ANALYSIS/*GENETICS Female Fluorescent Antibody Technique *Gene Expression Regulation, Viral Herpesvirus 6, Human/*GENETICS Human *HIV Long Terminal Repeat HIV-1/*GENETICS Papillomavirus/*GENETICS Polymerase Chain Reaction *Trans-Activation (Genetics) ABSTRACT
920830
M9281092

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .